Under mounting pressure in diabetes, Eli Lilly has just become the latest drugmaker to undergo a major shakeup.
Vas Narasimhan will take over as CEO of Novartis in February 2018 and will be inheriting several challenges, not the least of which is pricing pressure on both…
Kite investors are set for big gains with Gilead Sciences’ $180-per-share buyout—and founder Arie Belldegrun will reap a $597 million of that payday.
Novartis's groundbreaking CAR-T med won FDA approval Wednesday, but debate over pricing—and the company's responses—are just beginning.
Sanofi’s loss is Almirall’s gain. In its second diabetes exec shift since last May, EVP Peter Guenter jumped to the top job at derm-focused Almirall.
Shire has rolled out Mydayis, its new Adderall formulation, at a list price of $271 per month. The aim? Hitting $500 million in sales.
Know a woman in biotech, pharma or medtech making a mark in the industry? Nominate her for this year's Fiercest Women in Life Sciences feature.
A mutual fund that says it lost a mind-boggling $80 billion investing in Valeant alleges in a lawsuit that Valeant was a criminal enterprise.
Pfizer, Manhattan’s hometown drug company, has found brand-new digs, and they’ll be quite an improvement over its current 1960s-era HQ.
AstraZeneca has pegged big hopes on its clot-fighter Brilinta, and it's rolling out numbers designed to advance them. Will it work?